Compare BATL & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BATL | NXL |
|---|---|---|
| Founded | 1987 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.1M | 18.6M |
| IPO Year | N/A | 2022 |
| Metric | BATL | NXL |
|---|---|---|
| Price | $1.19 | $0.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 79.3K | ★ 113.8K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $183,422,000.00 | $156,931.00 |
| Revenue This Year | N/A | $38.28 |
| Revenue Next Year | N/A | $185.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $0.70 |
| 52 Week High | $3.67 | $4.19 |
| Indicator | BATL | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 37.05 |
| Support Level | $1.15 | $0.93 |
| Resistance Level | $1.25 | $1.01 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 27.60 | 6.76 |
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.